Close Menu

NEW YORK – 10x Genomics has countersued Bio-Rad Laboratories in a US District Court patent infringement suit.

Last week, 10x responded to Bio-Rad's allegations that 10x's Next GEM microfluidic chips infringe US Patent No. 10,190,115, "Methods and compositions for nucleic acid analysis" which covers the partitioning of a sample into droplets, in some cases.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.